After passing one speed bump, is the market heading towards more bumps in the road? Following the September sell-off, there has been a …
With the outbreak of the coronavirus, volatility has become a seemingly ever-present facet of the stock market. Since the end of February, the …
Canaccord’s Arlinda Lee cheers a new deal between Cara and VFMCRP that relieves financial pressure on the stock.
Laidlaw’s Francois Brisebois sings the praises of Cara’s significant licensing win as a doorway to commercial expertise and more credibility.
H.C.
New insights emerge in the biotech sector as Cara Therapeutics Inc (NASDAQ:CARA) released mixed results from a phase 2b trial of the company’s pain medication, …
Cara Therapeutics Inc (NASDAQ:CARA) reported mixed top-line Ph2b results of oral CR845 in osteoarthritis (OA) with patients receiving the top 5mg dose showing …
In a research note issued Friday, Cantor analyst Chiara Russo reiterated an Overweight rating on shares of Cara Therapeutics Inc (NASDAQ:CARA), while lowering …
Analysts are weighing in on biotechnology firms Peregrine Pharmaceuticals (NASDAQ:PPHM), Sarepta Therapeutics Inc (NASDAQ:SRPT), and Cara Therapeutics Inc (NASDAQ:CARA). Here’s a quick roundup of today’s …
Friday turned out to be a nightmare for shareholders of drug makers Peregrine Pharmaceuticals (NASDAQ:PPHM) and Cara Therapeutics Inc (NASDAQ:CARA), as the stocks price tumbled sharply in the wake …